PMA device
OmniaSecure MRI SureScan Lead Model 3930M
Medtronic, Inc. · Permanent Defibrillator Electrodes (NVY, Class III) · First FDA decision Apr 22, 2025, newest Apr 24, 2026Ventricular arrhythmia and sudden cardiac arrest
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
Breakthrough-designated
Device trials
2
Naming "OmniaSecure"
MAUDE reports
683
Brand "OmniaSecure", since 2015
PubMed studies
8
Mentioning "OmniaSecure"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing OmniaSecure MRI SureScan Lead Model 3930M
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 3 of 3 decisions filed under this name.
- OmniaSecure MRI SureScan Lead Model 3930MPMA supplement
P240036-S006 · Decided Apr 24, 2026 · 30 days after receipt · Normal 180 Day Track No User Fee
Device type: Permanent defibrillator electrodes (NVY) · Cardiology
- OmniaSecure MRI SureScan Lead Model 3930MBreakthroughPMA supplement
P240036-S004 · Decided Mar 9, 2026 · 90 days after receipt · Normal 180 Day Track
Device type: Permanent defibrillator electrodes (NVY) · Cardiology
- OmniaSecure MRI SureScan Lead Model 3930MBreakthroughPMA
P240036 · Decided Apr 22, 2025 · 186 days after receipt
Device type: Permanent defibrillator electrodes (NVY) · Cardiology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "OmniaSecure", any status and sponsor, newest update first.
- Lead Evaluation for Defibrillation and Reliability Post Approval StudyEnrolling by invitation
MedtronicPublic (MDT)
NCT07005232 · 2,000 participants (planned) · Start Jan 7, 2026 · Primary completion Sep 2032
Device: defibrillation lead · For: Tachyarrhythmia
Sites: Birmingham, Alabama; Chandler, Arizona; Little Rock, Arkansas · 97 sites in all
- Early Feasibility Study of 3930M Defibrillation Lead Implantation Via the Middle Cardiac Vein in Patients With Tricuspid Valve RegurgitationNot yet recruiting
Minneapolis Heart Institute FoundationAcademic, hospital or other
NCT07811609 · 5 participants (planned) · Start Nov 2026 · Primary completion Jan 2028
Device: Defibrillator · For: Defibrillator; Tricuspid Valve Regurgitation
Sites: Minneapolis, Minnesota
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "OmniaSecure", and for the whole product code for context.
This brand
683 reports: 349 malfunction, 324 injury, 9 death
Whole product code NVY
107,231 reports: 45,328 malfunction, 59,528 injury, 2,263 death
Newest reports for this brand
Medtronic Puerto Rico Villalba
2649622-2026-32186 · Received Oct 29, 2026 · Event dated Jun 26, 2026
Device type: Permanent Defibrillator Electrodes (NVY)
Device problem as coded: Over-Sensing
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- OmniaSecure¿ MRI SureScan¿Malfunction
Medtronic Puerto Rico Villalba
2649622-2026-32215 · Received Oct 29, 2026 · Event dated Oct 8, 2026
Device type: Permanent Defibrillator Electrodes (NVY)
Device problem as coded: Over-Sensing; Pacing Problem
Patient problem as coded: Bradycardia
- OmniaSecure¿ MRI SureScan¿Malfunction
Medtronic Puerto Rico Villalba
2649622-2026-31813 · Received Oct 27, 2026 · Event dated Oct 21, 2026
Device type: Permanent Defibrillator Electrodes (NVY)
Device problem as coded: Over-Sensing
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0285-2027 · Started Sep 17, 2026 · Posted by FDA Oct 23, 2026
Reason given: Affected leads require additional engineering evaluation due to complaints regarding difficulty in achieving fixation during implantation. Potential harm of tissue trauma due to implant difficulty.
Cause as FDA categorized it: Process design · Device type: Permanent Defibrillator Electrodes (NVY)
Published research
The most relevant PubMed records for "OmniaSecure"[tiab]. The summary above synthesizes these.
- Safety, efficacy, and reliability evaluation ofa novel small-diameter defibrillation lead: Global LEADR pivotal trial results.
Crossley GH, Sanders P, Hansky B, et al. · Heart Rhythm · 2024Multicenter Study, Randomized Controlled Trial
- Optimal lead preparation for the extraction of a lumenless defibrillation lead.
Schaller RD, Mondesert B, Manlucu J, et al. · Heart Rhythm · 2026
- Safety and performance of a novel defibrillation lead for left bundle branch area placement: Primary results of the LEADR LBBAP clinical trial.
Vijayaraman P, Liu X, Denman R, et al. · Heart Rhythm · 2026Clinical Trial, Multicenter Study
- High predicted durability for the novel small-diameter OmniaSecure defibrillation lead.
Crossley GH, Mason PK, Hansky B, et al. · Heart Rhythm · 2025Clinical Trial, Multicenter Study
- Safety, efficacy, and functional outcomes using a novel small-diameter defibrillation lead for left bundle branch area pacing: Final results of the LEADR LBBAP clinical trial.
Vijayaraman P, Mason PK, Liu X, et al. · Heart Rhythm · 2026
- Safety and Efficacy of the Novel OmniaSecure Defibrillation Lead Through Long-Term Follow-Up: Final Results From the LEADR Trial.
Crossley GH, Sanders P, Hansky B, et al. · Circ Arrhythm Electrophysiol · 2026Multicenter Study, Clinical Trial
- Sensing and detection performance of the novel, small-diameter OmniaSecure defibrillation lead: in-depth analysis from the LEADR trial.
Sanders P, Mason PK, Hansky B, et al. · Europace · 2025Adaptive Clinical Trial, Multicenter Study
- Initial real-world experience with the commercially available OmniaSecure defibrillation lead for left bundle branch-optimized cardiac resynchronization therapy (LOT-CRT).
Szaek-Goralewska A, Chmielewska-Michalak L, Barczyski M, et al. · Kardiol Pol · 2026
Other devices of this type
Also filed under product code NVY.
- Sprint Quattro Secure MRI SureScan Model 6947M leadMedtronic, Inc. · PMA 2022
- Attain Starfix LeadMedtronic, Inc. · PMA 2014
- Capsurefix Novus MRI Surescan Lead Model 5076Medtronic, Inc. · PMA 2016
- Passive Plus, Isoflex S&p, and Isoflex Optim LeadsAbbott Medical · PMA 2015
- Medtronic(R) Transvene Lead SystemMedtronic, Inc. · PMA 2020
- Selectsecure LeadMedtronic Cardiac Rhythm Disease Management · PMA 2016
- Medtronic 4195 Attain Starfix Model 4195 LV LeadMedtronic, Inc. · PMA 2014
- Capsure Epicardial Pacing LeadMedtronic, Inc. · PMA 2013
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.